← All trials
NCT03150914
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2017
- Primary completion
- Jun 6, 2020
- Completion date
- Jun 6, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CincinnatiLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of CincinnatiReponsible party - principal investigator
- University of CincinnatiStudy chair
- National Center for Advancing Translational Science (NCATS)Collaborator
- The LAM FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.